1974/04/01 by G. A. Roelofs · 2 citations
Medicine · #Pharmaceutical studies and practices #Attention Deficit Hyperactivity Disorder #Pharmacology and Obesity Treatment
paper · doi:10.1111/j.1600-0447.1974.tb08210.x
openalex publication_date 1974/04/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/05/21
A double‐blind, 6‐month trial of penfluridol and placebo was conducted in 15 chronic psychotic patients in the age range of 25–64 years. The patients, who had been well controlled with penfluridol for several months, were divided into two comparable groups with seven patients receiving penfluridol and eight receiving placebo. Dexetimide and other non‐psychotropic drugs already taken before the trial were continued. Each patient was assessed before and after 1, 2, 4 and 6 months of treatment using a 36‐item questionnaire. At the end of the trial, the weekly dosage of the double‐blind medication was two tablets of 20 mg or placebo in all patients. Whereas penfluridol‐treated patients maintained their improvement, placebo‐treated patients by the end of the trial had significantly deteriorated as regards direct psychotic phenomena and general behaviour.